Clinical Trial Update: Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update showing safety and pharmacokinetics data for ODM-201 (darolutamide) in castration-resistant prostate cancer; trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ODM-201 (darolutamide)

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-03-29